CHMP backs Novo Nordisk’s Sogroya for pediatric ISS
Novo Nordisk received a positive CHMP opinion recommending once-weekly Sogroya for children with idiopathic short stature in the EU. A European Commission decision covering ISS, SGA and Noonan Syndrome is expected later this year.
Novo Nordisk said the CHMP has issued a positive opinion recommending once-weekly Sogroya for children with idiopathic short stature in the EU. The European Commission decision on ISS, SGA and Noonan Syndrome is expected later this year.